Category Patents VS Innovation

FDA has low efficacy threshold for approving cancer medicines


Evergreening is common

The purported ‘innovation dip’ is an artefact of the time periods previously studied. Reports of declining innovation need to be considered in the context of their timescale and perspective.

A liberal economists perspective on why patents may not promote innovation.

IP on basic research reduces subsequent scientific research and product development

Voluntary licensing and tiered pricing are ineffective and help Gilead Sciences maintain market dominance – essay by Médecins du Monde

On Average 3.5 patents per drug in 2005! and How private-sector follow-on patents affect socially responsible licensing efforts.